Tze Chan, DO
Internal Medicine · Newton, IANPI 1376579706
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 1,052 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 50 manufacturers, the largest accounting for just 14.0% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,052 payments — averaging $12.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Pfizer$2K
- AbbVie$1K
- Boehringer Ingelheim$1K
- Amgen$827
- Novo Nordisk$732
- plus $6K from 44 others
What the payments were for
- Food & beverage$12,96499%
- Education$1361%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$812
- SYMBICORT$333
- BRILINTA$333
- BREZTRI AEROSPHERE$169
- PULMICORT RESPULES$164
- STIOLTO RESPIMAT$157
- SPIRIVA$157
- VOQUEZNA$125
- BREZTRI$118
- AIRSUPRA$118
How this compares
$13,100 in reported general payments places this provider in the 95th percentile of 583 internal medicine providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 223 | $226,388 |
| JardianceEmpagliflozin | 186 | $143,670 |
| EliquisApixaban | 239 | $140,322 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 88 | $87,731 |
| FarxigaDapagliflozin Propanediol | 97 | $69,799 |
| TrulicityDulaglutide | 27 | $39,732 |
| Tresiba Flextouch U-200Insulin Degludec | 40 | $38,659 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 73 | $35,943 |
| JanuviaSitagliptin Phosphate | 45 | $32,455 |
| XareltoRivaroxaban | 40 | $29,809 |
| MounjaroTirzepatide | 24 | $27,649 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 60 | $27,556 |
| Humalog Kwikpen U-200Insulin Lispro | 29 | $23,557 |
| LinzessLinaclotide | 41 | $21,682 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 24 | $17,808 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $732 | $226,388223 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $1,102 | $152,559204 claims |
| PfizerEliquis, Dilantin | $1,792 | $144,130258 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $532 | $123,732171 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,837 | $95,917155 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $490 | $67,38151 claims |
| AbbVieLinzess, Creon, Ubrelvy | $1,149 | $42,09266 claims |
| MerckJanuvia | $102 | $32,45545 claims |
| Johnson & JohnsonXarelto | $496 | $29,80940 claims |
| Astellas Pharma US IncMyrbetriq | $350 | $13,14919 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $97 | $6,63915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 583 internal medicine providers in Iowa.
Other internal medicine in Newton
- Mark JohnsonMason City$223K
- Mark CarlsonSioux City$174K
- Madalyn WalshIowa City$80K
- Alan KricsfeldCouncil Bluffs$49K
- Aziz HammoudIowa City$29K
- Matthew FryzekCouncil Bluffs$28K
- Diana Rabadi MararCouncil Bluffs$25K
- Isam MararCouncil Bluffs$23K
- Ali SaeedCedar Rapids$17K
- Lazaro RabangUrbandale$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.